Back to REGN
REGN: Growth, Valuation and Pipeline Risks
$REGNNEUTRALBiotechnology

REGN: Growth, Valuation and Pipeline Risks

Regeneron’s recent earnings beat, Dupixent and Eylea franchises, and expanding pipeline offer meaningful growth drivers. Yet the shares are near their 52-week high, analyst target datasets disagree, and competition for Eylea remains a key risk.

November 14, 202610 min read
Current Price
$955.47
+0.45%
Analyst Rating
Strong Buy
Price Target
$904.60
-5.3% upside
P/E Ratio
20.35

Executive Summary

Investment Thesis: Regeneron combines established antibody medicines, including Eylea and Dupixent, with a broad research pipeline and substantial financial resources. Its latest reported quarter beat the supplied EPS estimate, and recent data for an investigational POTS treatment adds a potential long-term catalyst, though it remains early-stage evidence. At $955.47 as of Friday, November 13, the shares are near their 52-week high, while the supplied analyst-target mean is below the closing price. The balance of operating momentum and valuation, competitive, and pipeline risks supports a neutral overall assessment.

Current Price: $955.47 | Key Metric: Q3 2026 EPS of $20.07 versus $16.51 estimated | Stance: NEUTRAL

US stock markets are closed Saturday, November 14. The latest price and daily change in this report refer to Friday, November 13, not Saturday trading. Market figures and analyst estimates can vary between providers, so differences are called out where relevant.

Company Overview

Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, manufactures, and commercializes medicines, with a focus on serious diseases. Its commercial portfolio spans areas including eye disease, immunology, cancer, and rare conditions, supported by a research platform that generates both company-developed medicines and collaborations.

Key Products & Competitive Position

  • Core Business: Research-led biologic drug development, with approved medicines and a pipeline of investigational treatments. Commercial products and collaborations contribute to the company’s revenue base.
  • Key Products: Eylea and the higher-dose Eylea HD address retinal diseases; Dupixent, developed with Sanofi, treats inflammatory conditions; other commercial and investigational programs include oncology and rare-disease treatments. Product performance and sales contributions can shift as competition, access, and clinical evidence change.
  • Competitive Moat: Regeneron’s antibody discovery capabilities, accumulated clinical and manufacturing expertise, established commercial relationships, and portfolio of marketed medicines provide important advantages. Those strengths don’t remove the risk that newer therapies, pricing pressure, or trial setbacks can affect growth.

Recent Developments

Recent coverage has highlighted sales momentum for Eylea HD and Dupixent, alongside competition facing the broader Eylea franchise. On November 12, the company presented Phase 2 results for baloncibart, an investigational NPR1-blocking antibody for postural orthostatic tachycardia syndrome, or POTS. The reported reduction in orthostatic heart rate and improvement in symptoms are encouraging signals, but a Phase 2 result is not proof of approval or commercial success. A November 13 filing-related news report also said AlphaCore Capital increased its position; institutional ownership changes are not evidence of future business performance.

Financial Snapshot

Market Cap$98.82B
P/E Ratio20.35
52-Week Range$591.52 - $991.73
Dividend Yield0.39%
EPS (TTM)$47.37
ROE15.07%

These headline figures use the supplied company profile and financial metrics. A separate Yahoo Finance data extract lists trailing EPS of $45.24 and ROE of 14.95%, so the reported trailing valuation and return ratios vary somewhat by data source and calculation date. The supplied price and EPS imply a P/E close to, but not exactly, the stated 20.35.

Revenue & Earnings Trends

The additional financial extract reports total revenue of approximately $16.90 billion, revenue growth of 36.3%, earnings growth of 35.5%, and quarterly earnings growth of 33.5%. It also reports net income of approximately $4.82 billion. These figures suggest strong recent growth in that dataset, but they don’t establish that the same pace will continue: quarterly product mix, collaboration revenue, pricing, and development expenses can all affect results.

For the quarter reported October 30, 2026, EPS was $20.07 against an estimate of $16.51, a $3.56 or roughly 21.6% beat. One quarter is useful evidence, not a complete trend. The next listed earnings report is expected January 28, 2027, with an EPS estimate of $25.39; that estimate is not company guidance.

Balance Sheet Highlights

The supplied current ratio of 3.35 and the additional extract’s quick ratio of 2.72 indicate substantial short-term coverage of liabilities. The same extract lists about $9.30 billion in cash, $2.71 billion in debt, and a debt-to-equity ratio of 8.08%. It also reports free cash flow of roughly $2.58 billion and operating cash flow of $4.85 billion. These figures point to financial flexibility, though the cash-flow figures and balance-sheet position should be checked against the company’s next filing for updates.

Valuation Analysis

Current Valuation Metrics

Forward P/E13.51Industry comparison not supplied
PEG Ratio1.16Growth-adjusted estimate
EV/EBITDA15.81Historical comparison not supplied
P/S Ratio5.85Peer comparison not supplied

The forward P/E, PEG, and EV/EBITDA figures come from the additional finance extract. The price-to-sales figure is an approximate calculation using the supplied $98.82 billion market capitalization and the extract’s $16.90 billion revenue, rather than a directly supplied ratio. Yahoo’s extract also reports enterprise value to revenue of 5.28, a different measure that incorporates debt and cash.

Historical Comparison

A five-year average valuation was not provided, so a precise historical premium or discount can’t be established from these inputs. The finance extract reports an average closing price of $681.96 over two years and a two-year total return of 23.26%, but those are price-performance figures, not valuation averages. A 37.78% 52-week change in the same extract and a 27.4% one-month rise cited in a news headline indicate a sharp recent run, which makes the price’s response to upcoming results and guidance especially relevant.

Fair Value Estimate

The supplied analyst consensus mean of $904.60 is about 5.3% below the Friday close, while a separate Yahoo Finance extract gives a mean target of $977.93, about 2.4% above it. The difference is material and likely reflects different analyst samples or update timing; neither is a guaranteed estimate of intrinsic value. The company’s cash generation and pipeline support a valuation case, while product concentration, Eylea competition, and clinical uncertainty argue for caution. A reliable DCF estimate would require assumptions for product-level growth, margins, development spending, and discount rates that aren’t provided here.

Competitive Landscape

Market Position

Market Share: Not supplied; market shares vary by drug and disease | Ranking: A major global biotechnology company with established branded medicines

Key Competitors

Eli Lilly and (LLY)Large biopharmaceutical company competing across immunology, oncology, and other therapeutic markets.
$NVSGlobal medicines developer with competing products and research programs in several specialty areas.
$SNYRegeneron’s Dupixent collaborator and a large pharmaceutical company with overlapping therapeutic interests.

These companies aren’t direct substitutes across every product. Competitive comparisons depend on the particular indication, treatment format, clinical outcomes, pricing, and reimbursement environment.

Competitive Advantages

  • Research Platform: Longstanding biologics research and antibody-development capabilities support discovery across multiple disease areas.
  • Commercial Reach: Established products, physician familiarity, and collaboration arrangements help the company bring medicines to market and reach patients.
  • Financial Capacity: Reported cash, operating cash flow, and a current ratio above 3 provide resources for research, manufacturing, and business development.

Earnings Track Record

Last 4 Quarters: 1 confirmed beat / 0 confirmed misses; 3 quarters not verified in supplied data

Recent Earnings History

Q3 2026$20.07 vs $16.51 estBEAT
Q2 2026Result and estimate not suppliedUNVERIFIED
Q1 2026Result and estimate not suppliedUNVERIFIED
Q4 2025Result and estimate not suppliedUNVERIFIED

The available Q3 figure is a clear beat against the estimate provided. It would be misleading to label the other three quarters as beats or misses without comparable actual and consensus EPS figures, so they’re left unverified rather than inferred.

Guidance Trend

No management guidance revisions were included in the supplied data. The January 28, 2027 EPS estimate of $25.39 is an external expectation, not company-issued guidance. Watch the next earnings release for product-level sales, full-year outlook, research spending, and any commentary on competition or demand.

Analyst Sentiment

Consensus Rating: Strong Buy, as labeled by the supplied consensus source

Strong Buy: 4Buy: 15Hold: 9Sell: 0Strong Sell: 1

The breakdown covers 29 analysts and is mixed despite the source’s Strong Buy consensus label: 19 ratings are Buy or Strong Buy, 9 are Hold, and 1 is Strong Sell. A separate finance extract reports 27 opinions and a recommendation mean classified as Buy, underscoring that analyst counts and labels differ across providers. These are third-party opinions, not a forecast guarantee.

Price Targets

  • Low: $756
  • Mean: $904.60 (-5.3% versus $955.47)
  • High: $1,100

The supplied analyst dataset also lists a median target of $875. A second dataset reports a low of $812, mean of $977.93, median of $982, and high of $1,175. Because these estimates differ, the figures above use the main supplied target set and should not be treated as a single definitive market view.

Recent Analyst Actions

No specific recent rating changes were provided. Zacks articles dated November 11 and 12 discussed Regeneron’s value characteristics, recent share performance, and product prospects, but those articles aren’t equivalent to a dated individual analyst rating change. The conflicting target averages are a reminder to check each estimate’s date and coverage before relying on it.

Recent News & Catalysts

Key Developments

  • POTS Phase 2 Data: Results presented November 12 reported reduced orthostatic heart rate and improved orthostatic symptoms with baloncibart. Further trials would be needed to establish durability, safety, and whether the medicine can ultimately reach patients.
  • Institutional Holding Report: A November 13 article said AlphaCore Capital LLC increased its REGN position by 133.5% in a reported quarter. The disclosure reflects one institution’s portfolio activity and doesn’t establish broader investor sentiment or future returns.
  • Product Growth and Competition: Recent commentary points to Eylea HD and Dupixent as important growth drivers, while noting intensifying competition for Eylea. Product-level sales, market share, and the pace of new treatment adoption remain important indicators to track.

Upcoming Catalysts

Next Earnings: Expected January 28, 2027 | Key Events: Q4 and full-year results, updated product sales and outlook, and clinical or regulatory updates for the pipeline

The POTS result is a pipeline milestone, not an approval event. Other forward catalysts may include clinical readouts and regulatory decisions, but no additional dates were supplied. Markets reopen Monday, November 16; this report does not identify a specific scheduled company event for that session.

Technical Outlook

Current Price: $955.47 as of Friday, November 13 vs 52-Week High: $991.73 (-3.7% from high)

Trend Analysis

Friday’s close was $4.28, or 0.45%, above the prior close of $951.19. The supplied Friday range was $942 to $961.94. The price sits near the top of its 52-week range, following the strong recent performance described in the news coverage. That positioning can reflect positive momentum, but it also leaves the shares sensitive to disappointments or changes in expectations. The supplied beta of 0.24 suggests historically lower sensitivity to broad market moves than a beta-one stock, though it doesn’t eliminate company-specific volatility.

Key Levels

  • Resistance: Around $961.94, the supplied Friday high, then $991.73, the 52-week high
  • Support: Around $942, the supplied Friday low, then approximately $875 to $905, near the supplied median and mean analyst targets

These are reference levels based on the limited price information supplied, not confirmed technical floors or ceilings. The 52-week low of $591.52 provides broader context but isn’t necessarily a near-term support level.

Bull vs Bear Case

Bull Case

  • Recent Earnings: Q3 EPS exceeded the supplied estimate by about 21.6%, and the additional dataset reports strong revenue and earnings growth.
  • Product and Pipeline Potential: Eylea HD and Dupixent are identified as growth drivers, while the POTS Phase 2 result adds a new development program to monitor.
  • Financial Resources: Cash exceeding reported debt, positive free cash flow, and strong short-term liquidity support investment in research and operations.

Bull Scenario Reference: $1,175, the higher target in the alternate analyst dataset, about 23% above Friday’s close. This is an external analyst estimate, not a forecast from this report.

Bear Case

  • Eylea Competition: Intensifying competition could pressure sales, pricing, or market share, including if newer formulations don’t offset erosion in existing products.
  • Pipeline Uncertainty: Phase 2 findings don’t establish approval, safety over longer periods, or commercial demand. Clinical setbacks could reduce expected future growth.
  • Target and Expectations Risk: The supplied target mean is below the current share price, and a sharp recent run can leave valuation expectations vulnerable to weaker results.

Bear Scenario Reference: $756, the low in the supplied analyst dataset, about 20.9% below Friday’s close. It is an analyst estimate, not a price prediction from this report.

Risks to Consider

  • Valuation Risk: The shares are near their 52-week high after a substantial recent gain. If expected product growth slows or estimates reset, valuation multiples and share price could come under pressure.
  • Competitive Risk: Eylea faces increasing competition, and other drug developers may challenge Regeneron across its markets. Product advantages can weaken as alternatives, delivery options, and reimbursement terms evolve.
  • Macro Risk: Healthcare policy, drug pricing and reimbursement decisions, interest rates, and changes in market appetite for biotechnology can affect revenue expectations and valuation.
  • Execution Risk: Clinical trials can fail or be delayed, regulatory reviews can require more evidence, and manufacturing or commercialization challenges can limit a medicine’s reach. Collaboration arrangements also shape economics and control for some products.

Other considerations include dependence on a relatively concentrated group of important medicines, differences between reported and adjusted earnings measures, and the possibility that analysts’ targets or forecasts become outdated. Low beta is historical context, not protection against a major clinical, regulatory, or company-specific development.

Bottom Line

Investment Verdict: NEUTRAL

Regeneron pairs established products and solid reported financial capacity with recent earnings momentum and a broad pipeline. However, the share price is close to its 52-week high, the main supplied analyst-target mean is below the Friday close, and Eylea competition and clinical uncertainty remain material. The evidence supports monitoring operating results and catalysts rather than treating either the positive analyst consensus or the recent price run as conclusive.

Action Items for Investors

  • Long-term investors: Compare product-level growth, pipeline progress, cash generation, and valuation assumptions with your own research horizon and risk tolerance; this analysis does not prescribe a position.
  • Short-term traders: Track the gap between Friday’s close, nearby price references, and any new company or sector news. Markets are closed Saturday and Sunday, with the next US trading session Monday, November 16.
  • Risk management: Consider how a clinical setback, price pressure, or slower sales could affect a biotechnology portfolio. Analyst targets and historical beta aren’t guarantees or substitutes for independent risk assessment.

What to Watch This Week

  • Any company updates or newly filed disclosures following the November 12 POTS presentation and November 13 institutional holding report.
  • REGN’s trading context when US markets reopen Monday, November 16, including whether the price remains near its recent range; no Saturday US equity trading occurred.
  • New analyst estimate changes and, further ahead, the expected January 28, 2027 earnings report, especially product sales, outlook, and pipeline updates.

This report is for informational purposes only and is not investment advice. Data and analyst estimates may be incomplete or differ by provider. Verify current company filings and market information before drawing your own conclusions.

Share this report

Share this article

Spread the word on social media

Think REGN will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.